

Supporting Information

Screen and Optimization of Phage Display Cyclic Peptides Against WDR5 WBM Site

Lingyu Song,^{a,b} Jiawen Cao,^{a,b} Lin Chen,^b Zhiyan Du,^b Naixia Zhang,^{a,c} Danyan Cao^{*b} and Bing Xiong^{*a,b,d}

^a Department of College of Pharmacy, University of Chinese Academy of Sciences, 19A Yuquan Road, Beijing 100049, China.

Email: bxiong@simm.ac.cn (B. Xiong); caody@simm.ac.cn (D. Cao); s20-songlingyu@simm.ac.cn (L. Song)

^b Department of Medicinal Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

^c Department of Analytical Chemistry, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

^d State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Shanghai 201203, China

Table of Contents

Table S1. Phage titer and recovery efficiency of three rounds in the biopanning	1
Table S2. The peptide sequences derived from the third round in the subtractive panning	3
Table S3. The peptide sequences derived from the third round in the alternant panning	4
Table S4. Purify and molecular weight of cyclization products with 9 different chemical linkers	5
Table S5. The HPLC gradient elution condition.....	6
Figure S1. The characterization of purified his-tagged WDR5	7
Figure S2. Phage-displayed cyclic peptide sequences picked from the third round of biopanning	8
Figure S3. Binding affinity derived from HTRF assay of the positive control peptide SV-10.	9
Figure S4. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC3	10
Figure S5. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC4	11
Figure S6. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC7	12
Figure S7. The analysis certification of the synthetic peptide DH226015	13
Figure S8. The analysis certification of the synthetic peptide D210012	14
Figure S9. The analysis certification of the synthetic peptide D210014	15
Figure S10. The analysis certification of the synthetic peptide DH226016	16
Figure S11. The analysis certification of the synthetic peptide DH210901	17
Figure S12. The analysis certification of the synthetic peptide DH226027	18
Figure S13. The analysis certification of the synthetic peptide DH226027-L.....	19
Table S1. Phage titer and recovery efficiency of three rounds in the biopanning; recovery efficiency = output titer / input titer	

Round	Input Titer (pfu)	Output Titer (pfu)	Recovery Efficiency	Fold Increase
Subtractive panning with Ni-NTA magnetic agarose beads				
1	1.0×10^{11}	1.0×10^4	1.0×10^{-7}	1
2	2.0×10^{11}	7.0×10^4	3.5×10^{-7}	3.5
3	2.0×10^{11}	1.0×10^4	0.5×10^{-7}	0.5
Alternant panning with two kinds of magnetic beads				
1	1.0×10^{11}	2.0×10^6	2.0×10^{-3}	1
2	2.0×10^{11}	4.0×10^5	2.0×10^{-4}	0.1
3	2.0×10^{11}	2.5×10^8	1.25×10^{-1}	62.5

Table S2. The peptide sequences derived from the third round in the subtractive panning; *: the sequence with an affinity value lower than -21.0

No.	Peptide Sequence	Reads (Sanger)	PSBinder (SAROTUP)	Affinity (ADCP)
A1	CAHQRWVTC	4/33	0.93	-
A2	CPWQVHRDC	3/33	0.53	error
A3	*CADTNWLVC	2/33	0.52	-22.7
A4	CSSNTVPAC	2/33	0.04	-19.6
A5	CPWKTHQSC	2/33	0.17	error
A6	CSEARWMRC	2/33	0.12	-20.2
A7	*CSQAWWYQC	1/33	0.24	-22.7
A8	CPWKVHSYC	1/33	0.81	-
A9	*CPNQWKSYC	1/33	0.27	-22.0
A10	CNNLNAILC	1/33	0.08	-20.2
A11	*CFLNVSNAC	1/33	0.25	-21.1
A12	CDMPPTQKC	1/33	0.55	-19.7
A13	CWHAGRWTG	1/33	0.78	-
A14	CLPNDHLRC	1/33	0.20	error
A15	CGSSRWLEC	1/33	0.79	-

Table S3. The peptide sequences derived from the third round in the alternant panning; *: the sequence with an affinity value lower than -21.0

No.	Peptide Sequence	Reads (Sanger)	PSBinder (SAROTUP)	Affinity (ADCP)
B1	*CGSLDWPHC	5/124	0.69	-22.8
B2	CMTPNPTTC	2/124	0.35	-17.2
B3	CRAYDFPSC	2/124	0.97	-
B4	CDARGGLRC	2/124	0.37	-20.2
B5	CRVYEWPKC	1/124	0.98	-
B6	CRALPFNTC	1/124	0.34	-18.6
B7	CRVL PYGSC	1/124	0.94	-
B8	CRVHPVGEC	1/124	0.97	-
B9	CRDKPSNVC	1/124	0.21	-18.7
B10	CGTNPIKKC	1/124	0.27	-17.9
B11	CGSNTTVEC	1/124	0.57	-20.6
B12	CSSNTVPAC	1/124	0.04	-19.6
B13	CVSTATNGC	1/124	0.39	-19.1
B14	*CNSLNWFWC	1/124	0.30	-22.2
B15	CSKKNPSWC	1/124	0.25	-19.1
B16	CYGLSNSRC	1/124	0.40	-19.9
B17	*CGEGEADVC	1/124	0.50	-22
B18	CAIGETSTC	1/124	0.89	-
B19	CLNVSSPTC	1/124	0.10	-18.3
B20	CNNPAQPWC	1/124	0.19	-17.8
B21	CEPRSLANC	1/124	0.10	-19.2
B22	CNWRLSNYC	1/124	0.18	error
B23	CMNEDKFHC	1/124	0.53	error
B24	CTGPWIWHC	1/124	0.96	-
B25	CVNSMTPC	1/124	0.04	error
B26	CINNLPKSC	1/124	0.12	-19.1
B27	CFPNVYHAC	1/124	0.24	error
B28	CSRSMNMAC	1/124	0.34	-18.6
B29	CHMYHNATC	1/124	0.00	error
B30	CHLTHQASC	1/124	0.00	error

Table S4. Purify and molecular weight of cyclization products with 9 different chemical linkers

Product	Purify	Theoretical M.W.	Calculated M.W.	Observed [M+H] ⁺	Intensity
CYC1	-	1273.50	1274.50	1274.59	1.87E+08
CYC2	-	1273.50	1274.50	1274.52	4.51E+07
CYC3	92.90%	1273.50	1274.50	1274.53	2.43E+06
CYC4	80.98%	1223.49	1224.49	1224.58	5.74E+06
CYC5	-	1225.47	1226.47	1294.37	8.03E+06
CYC6	-	1264.44	1265.44	1462.38	8.17E+06
CYC7	89.00%	1274.50	1275.50	1275.56	4.91E+06
CYC8	-	1269.47	1270.47	1170.51	1.59E+08
CYC9	-	1223.49	1224.49	1170.60	5.70E+07

Table S5. The HPLC gradient elution condition

Time (min)	Mobile Phase A (%)	Mobile Phase B (%)
0.0	20.0	80.0
2.0	95.0	5.0
5.0	60.0	40.0
6.5	5.0	95.0
8.0	5.0	95.0
8.5	95.0	5.0




Figure S1. The characterization of purified his-tagged WDR5. (A) Gel-filtration chromatogram of his-tagged WDR5 with a single peak at 89 ml. (B) The elution volume of aggregated WDR5 at 47 ml. (C) SDS-PAGE of purified his-tagged WDR5 protein migrating above the band 35.0 kDa.

A

1	CADTNWLVC
2	CADTNWLVC
3	CSSNTVPAC
4	CSSNTVPAC
5	CSQAWWYQC
6	CPWKTHQSC
7	CPWKTHQSC
8	CPWKVHSYC
9	CPNQWKSYC
10	CNNLNAILC
11	CFLNVSNAC
12	CDMPPTQKC
13	CPWQVHRDC
14	CPWQVHRDC
15	CPWQVHRDC
16	CAHQRWVTC
17	CAHQRWVTC
18	CAHQRWVTC
19	CAHQRWVTC
20	CSEARWMRC
21	CSEARWMRC
22	CGSSRWLEC
23	CWHAGRWT
24	CLPNDHLRC
25	CRTL PYKWC
26	CRTL PYKWC
27	CRTL PYKWC
28	CRTL PYKWC
29	CRTL PYKWC
30	CRTL PYKWC
31	CRTL PYKWC
32	CRTI PYNNC
33	CRTI PYNNC

B

1	CGSLDWPHC	42	CRTI PFPTC	83	CRTL PYQGC
2	CGSLDWPHC	43	CRTI PFPTC	84	CRTL PYWGC
3	CGSLDWPHC	44	CRTI PFPTC	85	CRTL PWDFC
4	CGSLDWPHC	45	CRTI PFPHC	86	CRTL PWMTC
5	CGSLDWPHC	46	CRTL PFPPEC	87	CRTL PWMTC
6	CHLTHQASC	47	CRTL PFPDC	88	CRTL PWNQC
7	CSRSMNMAC	48	CRTL PFPFC	89	CRTL PWSMC
8	CHMYHNATC	49	CRTWP FPPTC	90	CRTL PHNMC
9	CMTPNPTTC	50	CRTQP FPNC	91	CRTL PHNMC
10	CMTPNPTTC	51	CRTQP FPNC	92	CRTL PHNEC
11	CRAYDFPSC	52	CRTQP FPNC	93	CRTL PHGAC
12	CRAYDFPSC	53	CRTL PFNTC	94	CRTL PHGAC
13	CDARGGLRC	54	CRTL PFNTC	95	CRTL PYGVC
14	CDARGGLRC	55	CRTL PFNTC	96	CRTL PYGLC
15	CRVYEWPKC	56	CRTL PFNTC	97	CRTMPLSCL
16	CRALPFNTC	57	CRTL PFLTC	98	CRTL PMGLC
17	CRVLPYGSC	58	CRTVP FNLC	99	CRTMPVGTC
18	CRVHPVGE	59	CRTL PFTQC	100	CRTMPVGTC
19	CRDKPSNVC	60	CRTL PFTQC	101	CRTL PI GTC
20	CGTNPPIKKC	61	CRTL PYTSC	102	CRTL PLTV
21	CGSNTTVEC	62	CRTL PVFGQC	103	CRTEPFMH
22	CSSNTVPAC	63	CRTL PVFGSC	104	CRTEPFMH
23	CVSTATNGC	64	CRTL PVFGSC	105	CRTAPFMH
24	CNSLNFWC	65	CRTL PFEAC	106	CRTAPFMH
25	CSKKNPSWC	66	CRTL PFIAC	107	CRTVPYMH
26	CYGLNSNSRC	67	CRTL PYHIC	108	CRTQP YLYC
27	CGEGEADVC	68	CRTL PYHHC	109	CRTQPFLY
28	CAIGETSTC	69	CRTL PYHYC	110	CRTVPHMYC
29	CLNVSSPTC	70	CRTL PHEC	111	CRTHPYEYC
30	CNNPAQPWC	71	CRTL PYLQC	112	CRTMPNMAC
31	CEPRSLANC	72	CRTL PYFEC	113	CRTVPLQQC
32	CVNSMTYP	73	CRTL PYYT	114	CRTTPLMQC
33	CNWRLSNYC	74	CRTMPYKQC	115	CRTEPLMKC
34	CMNEDKFHC	75	CRTL PYRDC	116	CRTQP YIEC
35	CTGPWIWHC	76	CRTMPYMNC	117	CRTL PVKEC
36	CFPNVYHAC	77	CRTVPYLSC	118	CRTEPVKLC
37	CINNLPKSC	78	CRTVPYMSC	119	CRTMEYWRC
38	CRTGSAWSC	79	CRTVPYMSC	120	CRTL QYMSC
39	CRTYEFPK	80	CRTVPYMSC	121	CRTL SYGSC
40	CRTHWWPQC	81	CRTVPYPGC	122	CRTVAYMKC
41	CRTL TINQC	82	CRTL PYLGC	123	CRTLEFSVC
				124	CRTVEMEAC

Figure S2. Phage-displayed cyclic peptide sequences picked from the third round of biopanning; numbers of the enriched sequences are marked by green colour. (A) 33 sequences picked from the subtractive panning with Ni-NTA magnetic agarose beads. (B) 124 sequences picked from the alternant panning with two kinds of magnetic beads.




Figure S3. Binding affinity derived from HTRF assay of the positive control peptide SV-10.




Figure S4. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC3.




Figure S5. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC4.








Figure S6. HPLC chromatogram and LC-MS spectrum of the cyclic peptide CYC7.



Sample Information		Interface		Prerod Bias	
Dissolution method	: 0.1mg sample dissolved to 50%ACN and 50%H2O	Nebulizing Gas Flow	: 1.50L	+: 4.5kv	
Date Acquired	: 2022/07/11 12:08:17	CDL Temp	: 250°C	Detector T. Flow	:-0.2kv
Injection Volume	: 1ul	CDL Volt	: 200	B. conc	: 0.2ml/min
Name	DH226015	Block Temp			: 50%H2O/50%MeOH
Sequence	: CADTNWLVC				
Modification	: C-C				
Lot No.	B-06-1005				
Theoretical bserveed	: 1022.17				


Figure S7. The analysis certification of the synthetic peptide DH226015.



PeakTable

	名称	保留时间 (分钟)	% 面积	面积 (微伏*秒)	高度 (微伏)
1		6.539	0.08	8271	991
2		7.173	0.40	43341	4174
3		7.683	99.41	10778724	790266
4		8.273	0.12	12626	1022

MS Spectrum




名称 峰1 保留时间 1.038 基础峰 564.30 样品名称 D210012

Figure S8. The analysis certification of the synthetic peptide D210012.


产品名称:
 Peptide Name: Custom Peptide
 订单编号:
 Purchase order number: D210014
 批号:
 Lot Number: FM-02-0006
 多肽序列:
 Sequence: H-Cys-Ser-Gln-Ala-Trp-Tyr-Gln-Cys-OH (Cys&Cys bridge)
 分子量:
 Molecular Weight (daltons): 1172.3
 纯度:
 Final Purity (HPLC %): 97.6%
 产品重量:
 Amount Supplied: 5 mg
 产品外观:
 Appearance: White lyophilized powder
 储存条件:
 长期储存 Long Term: -20°C
 Storage Conditions: 短期储存 Short Term: 2°C~8°C

Chromatogram



名称	保留时间 (分钟)	% 面积	面积 (微伏·秒)	高度 (微伏)
1	10.800	0.05	9177	1166
2	11.066	0.10	18632	2786
3	11.314	0.60	113501	14223
4	11.788	97.60	18338575	2133439
5	12.087	1.13	212043	22559
6	12.429	0.21	39204	4744
7	12.740	0.22	42201	5523
8	12.933	0.09	16340	2891



MS Spectrum



名称 峰1 保留时间 2.736 基础峰 1172.76 样品名称 D210014

Figure S9. The analysis certification of the synthetic peptide D210014.



产品名称:
 Peptide Name: Custom Peptide
 订单编号:
 Purchase order number: DH226016
 批号:
 Lot Number: B-06-1006
 多肽序列:
 Sequence: H-Cys-Phe-Leu-Asn-Val-Ser-Asn-Ala-Cys-OH (Cys&Cys bridge)
 分子量:
 Molecular Weight (daltons): 968.12
 纯度:
 Final Purity (HPLC %): 96.5%
 产品重量:
 Amount Supplied: 4 mg
 产品外观:
 Appearance: White lyophilized powder
 储存条件:
 Long Term: -20°C
 Storage Conditions: Short Term: 4°C



Sample Information
 Dissolution method : 0.1mg sample dissolved in 0.1mL acetonitrile and water (50%ACN and 50%H2O)
 Date Acquired : 2022/07/12 16:38:23
 Injection Volume : 1μL
 Name : DH226016
 Sequence : CFLNVSNAC
 Modification C-C:
 Lot No. : B-06-1006
 Theoretical M.W. : 968.125
 Observed M.W. :

Figure S10. The analysis certification of the synthetic peptide DH226016.

产品名称:
 Peptide Name: Custom Peptide
 订单编号:
 Purchase order number: DH210901
 批号:
 Lot Number: A-09-1001
 多肽序列:
 Sequence: H-Cys-Gly-Ser-Leu-Asp-Trp-Pro-His-Cys-OH (Cys&Cys bridge)
 分子量:
 Molecular Weight (daltons): 1015.14
 纯度:
 Final Purity (HPLC %): 95.4%
 产品重量:
 Amount Supplied: 5 mg
 产品外观:
 Appearance: White lyophilized powder
 储存条件:
 Long Term: -20°C
 Storage Conditions: Short Term: 4°C





Sample Information
 Dissolution method : 0.1mg sample dissolved to 100%H2O
 Date Acquired : 2021/10/12 11:22:03
 Injection Volume : 1ul
 Name DH210901
 Sequence : CGSLDWPHC
 Modification : C-C
 Lot No. A-09-1001
 Theoretical bserve : 1015.14

Interface : ESI
 Nebulizing Gas Flow : 1.50L
 CDL Temp : 250°C
 CDL Volt : 200
 Block Temp : 200
 Prerod Bias : +4.5kv
 Detector : -0.2kv
 T. Flow : 0.2ml/min
 B. conc : 50%H2O/50%MeOH

Figure S11. The analysis certification of the synthetic peptide DH210901.



产品名称:
 Peptide Name: Custom Peptide
 订单编号:
 Purchase order number: DH226027
 批号:
 Lot Number: B-08-1009
 多肽序列:
 Sequence: H-Cys-Asn-Ser-Leu-Asn-Trp-Phe-Trp-Cys-OH (Cys&Cys bridge)
 分子量:
 Molecular Weight (daltons): 1170.33
 纯度:
 Final Purity (HPLC %): 98.0%
 产品重量:
 Amount Supplied: 4 mg
 产品外观: 白色冻干粉
 Appearance: White lyophilized powder
 储存条件: 长期储存 Long Term: -20°C
 Storage Conditions: 短期储存 Short Term: 4°C



Sample Information		Interface	:ESI	Prerod Bias :+4.5kv
Dissolution method	:0.1mg sample dissolved in 50%ACN and 50%H2O	Nebulizing Gas Flow	:1.50L	Detector :−0.2kv
Date Acquired	:2022/08/04 09:44:11	CDL Temp	:250°C	T. Flow :0.2ml/min
Injection Volume	:1μl	CDL Volt		B. conc :50%H2O/50%MeOH
Name	DH226027	Block Temp	:200	
Sequence	:CNSLNWFWC			
Modification	:C-C			
Lot No.	B-08-1009			
Theoretical	:1170.339			
bserved				

Figure S12. The analysis certification of the synthetic peptide DH226027.

产品名称:
 Peptide Name: Custom Peptide
 订单编号:
 Purchase order number: DH226027-L
 批号:
 Lot Number: A-11-1001
 多肽序列:
 Sequence: H-Cys-Gly-Ser-Leu-Asp-Trp-Pro-His-Cys-OH
 分子量:
 Molecular Weight (daltons): 1017.14
 纯度:
 Final Purity (HPLC %): 99.4%
 产品重量:
 Amount Supplied: 100 mg
 产品外观:
 Appearance: White lyophilized powder
 储存条件:
 Long Term: -20°C
 Storage Conditions: Short Term: 4°C



Sample Informati		Interface	:ESI	Prerod Bias	:+4
Dissolution method	:0.1mg sample dissolved in	Nebulizing Gas Flow	:1.50L	Detector	:
100%H2O	100%H2O	CDL Temp	:250°C	T. Flow	:0.2ml/min
Date Acquired	:2021/11/11 14:41:06	CDL Volt		B. conc	:50%H2O/50%MeOH
Injection Volume	:1μl	Block Temp	:200		
Name	DH226027-L				
Sequence	:CGSLDWPHC				
Modification	:N/A				
Lot No.	A-11-1001				
Theoretical	:1017.14				
bserved					

Figure S13. The analysis certification of the synthetic peptide DH226027-L.